small molecule

YUTREPIA

TREPROSTINIL SODIUM

Loss of exclusivityMay 2037latest FDA-listed patent expiry

CompanyLiquidia Technologies →View the full company profile on CliffBio

Drug detail

Brand name	YUTREPIA
Active ingredient	TREPROSTINIL SODIUM
Strength	EQ 0.0795MG BASE/INH
Dosage form	POWDER
Route	INHALATION
Modality	Small molecule
FDA approval	May 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
11712442	May 2037	use U-4200
10898494	May 2037	use U-4200
11660304	May 2037	use U-4200
11744836	May 2037	product
11744835	May 2037	product
12390475	May 2037	product

Regulatory exclusivity

Code	Expires
NP	May 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Liquidia Technologies